INTRODUCTION
============

Proper vascular access is essential to provide efficient dialysis therapy. Vascular access complications remain the leading cause of morbidity in hemodialysis patients and are a major contributor to high healthcare costs. The central venous catheter has been linked to greater risk of infection, hospitalization, and mortality, and has been known to compromise dialysis adequacy \[[@b1-kjim-2017-025]-[@b7-kjim-2017-025]\]. As a result, arteriovenous fistula (AVF) use is strongly recommended by many guidelines \[[@b8-kjim-2017-025]-[@b12-kjim-2017-025]\].

Over the years, there has been marked growth in the use of dialysis to treat elderly patients. In Korea, patients aged ≥ 65 years increased to 37.5% of the total number of dialysis patients \[[@b13-kjim-2017-025]\]. There is, however, controversy about the benefits of AVF compared with the use of central vascular catheter, especially for elderly or very old-aged patients \[[@b14-kjim-2017-025],[@b15-kjim-2017-025]\]. Treatment challenges among elderly patients include comorbid conditions and non-maturing fistula \[[@b16-kjim-2017-025]\]. In addition, elderly patients have notable differences in kidney function, timing and initiation of dialysis, quality-of-life issues, and life expectancy \[[@b17-kjim-2017-025]\]. However, clinical practice guidelines are rarely age-specific and do not address issues specific to the well-being of elderly patients. Despite established guidelines, a very high proportion of patients start dialysis with a central venous catheter because of late referral to a nephrology team \[[@b18-kjim-2017-025],[@b19-kjim-2017-025]\] and the increased use of hemodialysis for acute kidney injury (AKI).

The association between initial vascular access for hemodialysis and mortality is strongly linked, and AVF has been shown to be of benefit in a survival analysis of hemodialysis patients \[[@b20-kjim-2017-025]\]. However, a previous study suggests that the association between the use of a central venous catheter and mortality might be the result of AKI itself, and that mortality for patients implanted with a central venous catheter may be confounded without considering the influence of an acute dialysis start \[[@b21-kjim-2017-025],[@b22-kjim-2017-025]\]. There was also a selection bias because patients receiving the central venous catheter were in worse vascular condition or had more comorbidities. Despite careful adjustment for various factors, it remains difficult to account for bias. Most patients who begin hemodialysis via central venous catheter change to arteriovenous (AV) access, including AVF and AV graft, in the long run. However, physicians also considered conversions in light of the patient's age, remaining life expectancy, and comorbid condition. The aim of the present study was to demonstrate whether the association between initial vascular access and all-cause mortality among hemodialysis patient might vary at different ages and conversion rate might differ according to age.

METHODS
=======

Ethics statement
----------------

This study was approved by the Institutional Review Board of Chonnam National University Hospital, Gwangju, Korea (CNUH-2012-108). The study was performed in accordance with the Helsinki Declaration of 1975, as revised in 2000. The Institutional Review Board waived the need for consent given the retrospective design of the project. The mortality data were determined from government death records from Statistics Korea.

Subjects
--------

We conducted a retrospective study of 2,552 patients who started hemodialysis at Chonnam National University Hospital between March 2005 and December 2012. Subsequently, 507 patients who did not survive the first 3 months after initiation of hemodialysis were excluded because outcomes may be influenced by a patient's health status before hemodialysis commencement rather than type of vascular access. For the final study, 2,045 patients were enrolled ([Fig. 1](#f1-kjim-2017-025){ref-type="fig"}). Patients in the survey were diagnosed with AKI or chronic kidney disease and underwent hemodialysis treatment for more than three consecutive months. We presupposed that the bias of an acute dialysis start or risk of AKI itself could be reduced by this exclusion. Hemodialysis was conducted via central venous catheter or AV access. The central venous catheter is associated with percutaneous catheter and tunneled cuffed catheter; and AV access is associated with AVF and AV graft. Three months after hemodialysis initiation, vascular access was reinvestigated because many patients underwent an AV access operation for long-term hemodialysis. The following patients were excluded: those who did not receive later vascular access (n = 296), those who did not maintain renal replacement therapy (n = 131), and those who underwent kidney transplantation or conversion to peritoneal dialysis (n = 108). Patients were subdivided into three age groups (\< 65, 65 to 74, and ≥ 75 years). Demographic, clinical, and laboratory parameters, including creatinine, hemoglobin, and albumin levels, and treatment data were obtained from electronic patient records. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula: mL/min/1.73 m^2^ = 141 × minimum (creatinine/k, 1)^α^ × maximum (creatinine/k, 1)^--1.209^ × 0.993^age^ × 1.018 (if, female) × 1.159 (if, black), where κ is 0.7 for women and 0.9 for men, and α is --0.329 for women and --0.411 for men \[[@b23-kjim-2017-025]\]. The patient's vascular access was divided into three categories (percutaneous catheter, tunneled cuffed catheter, and AV access). Follow-up for the whole group of patients was 35.2 ± 21.72 months.

Statistical analysis
--------------------

Continuous variables with normal distributions are presented as means ± standard deviation and were compared using one-way ANOVA. Pearson chi-squared test was used to evaluate differences between categorical variables. Survival curves were compared by log-rank tests. Multivariable Cox regression analysis was applied to adjust for the baseline factors: e.g., age, gender, diabetes, heart failure, cardioprotective medication (e.g., β-blocker, calcium channel blocker, angiotensin converting enzyme inhibitor, angiotensin receptor antagonist medication) and hemodialysis vascular access. Cox proportional hazards regression analysis was performed to evaluate the prognostic significance of initial vascular access for mortality in hemodialysis patients. All statistical tests were performed using the SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). *p* values \< 0.05 were considered significant.

RESULTS
=======

Baseline characteristics
------------------------

A total of 2,045 patients (59% male) were included in the study. The mean age was 58.5 ± 14.5 years. Three age categories were evaluated for patients who initiated hemodialysis. At baseline, 58.2% (n = 1,191) of the patients were \< 65 years old, 28.7% (n = 586) were 65 to 74 years old, and 13.1% (n = 268) were ≥ 75 years old. The percentage of hemodialysis patient ≥ 65 years was 41.8%. Percutaneous catheter use accounted for 39.8% (n = 815) of all incident hemodialysis patients, whereas tunneled cuffed catheter accounted for 24.0% (n = 491) and AV access accounted for 36.1% (n = 739). [Table 1](#t1-kjim-2017-025){ref-type="table"} shows the patients' baseline characteristics by vascular access type. In general, across all age categories, patients who were female and who had lower serum hemoglobin levels, lower serum albumin levels, increased white blood cell levels, increased C-reactive protein levels, and who used inotropic or vasopressor agents were more likely to receive a percutaneous catheter or tunneled cuffed catheter than AV access. [Table 2](#t2-kjim-2017-025){ref-type="table"} lists the baseline characteristics of the study population by age category. There was a trend toward increased percutaneous catheter or tunneled cuffed catheter use for older patients (≥ 75 years) than those aged \< 65 years or those 65 to 74 years old (*p* = 0.001). There were no differences in hemoglobin, sodium, or albumin levels among the groups. Although serum creatinine level decreased with increasing age, there was no difference in eGFR among the three groups.

Initial vascular access-associated mortality by age group
---------------------------------------------------------

In all, 716 patients (35.0%) died and overall mortality increased with age (23.6%, 46.6%, and 48.0% for patients aged \< 65, 65 to 74, and ≥ 75 years, respectively; *p* = 0.001). We investigated the impact of initial vascular access on 5-year mortality. [Fig. 2](#f2-kjim-2017-025){ref-type="fig"} showed 5-year survival in patients starting hemodialysis according to age and vascular access, patients aged ≥ 65 years with central venous catheter showed the lowest survival curve, whereas patients aged \< 65 years with AV access showed the highest survival curve (log-rank test; *p* \< 0.001). Kaplan-Meier survival analysis showed that the survival rate for patients with central venous catheter aged 65 to 74 and ≥ 75 years was reduced, but not for those aged \< 65 years (log-rank test; *p* \< 0.001, *p* = 0.007, and *p* = 0.278, respectively) ([Fig. 3](#f3-kjim-2017-025){ref-type="fig"}).

To determine risk factors for 5-year mortality in patients starting hemodialysis, Cox proportional analysis was performed ([Table 3](#t3-kjim-2017-025){ref-type="table"}). In adjusted Cox proportional analysis; age per years (hazard ratio \[HR\], 1.04; 95% confidence interval \[CI\], 1.03 to 1.05); diabetes (HR, 1.88; 95% CI, 1.59 to 2.21); albumin \< 3.5 g/dL (HR, 1.43; 95% CI, 1.22 to 1.68); and hemoglobin \< 10.0 g/dL (HR, 1.17; 95% CI, 1.00 to 1.37). Compared with AV access, percutaneous catheter (HR, 1.78; 95% CI, 1.44 to 2.21) and tunneled cuffed catheter (HR, 1.64; 95% CI, 1.36 to 1.98) were significant risk factors for 5-year mortality in patients starting hemodialysis.

[Table 4](#t4-kjim-2017-025){ref-type="table"} showed the differences in 5-year mortality in patients starting hemodialysis according to vascular access types and age group. The overall 5-year mortality in all subjects was 31.0% (634/2,045). The 5-year mortality was increased in the order of AV access, tunneled cuffed catheter and percutaneous catheter, and also increased with age. An increased risk for death in the hemodialysis patients with percutaneous catheter was more pronounced in older subjects: in patients aged ≥ 75 years (HR, 2.78; 95% CI, 1.92 to 4.03); in patients aged 65 to 74 years (HR, 2.43; 95% CI, 1.82 to 3.23) as compared with patients aged \< 65 years (HR, 1.18; 95% CI, 0.89 to 1.56), the value of *p* for interaction between vascular access and age group is \< 0.001. [Table 5](#t5-kjim-2017-025){ref-type="table"} lists associations between vascular access and 5-year mortality in increasingly adjusted models. Compare to AV access, percutaneous catheter and tunneled cuffed catheter were risk factors for patients aged 65 to 74 years and those ≥ 75 years. After fully adjusting for potential confounding factors including vascular conversion, patients aged \< 65 years, percutaneous and tunneled cuffed catheter, were not associated with 5-year mortality (\[HR, 1.28; 95% CI, 0.89 to 1.82\] and \[HR, 1.04; 95% CI, 0.74 to 1.45\], respectively). On the other hand, for patients aged 65 to 74 and ≥ 75 years, percutaneous catheter (\[HR, 1.97; 95% CI, 1.35 to 2.74\] and \[HR, 1.93; 95% CI, 1.35 to 2.74\], respectively) and tunneled cuffed catheter (\[HR, 1.89; 95% CI, 1.10 to 3.26\] and \[HR, 1.34; 95% CI, 1.05 to 2.26\], respectively) were significantly associated with 5-year mortality.

Vascular access conversion after 3 months by age group
------------------------------------------------------

Conversion rate means the proportion of patients who changed their vascular access type from central venous catheter to AV access or who underwent AV access creation. As age increased, the conversion rate decreased (94.14%, 90.54%, and 80.37% for each age group; *p* = 0.001) ([Table 2](#t2-kjim-2017-025){ref-type="table"}).

[Fig. 4](#f4-kjim-2017-025){ref-type="fig"} shows the proportion of vascular access both at the time of hemodialysis initiation and 3 months after hemodialysis initiation among the three age categories. Most patients who initiated hemodialysis therapy using a central venous catheter exchanged vascular access to AV access (94.1%) ([Table 2](#t2-kjim-2017-025){ref-type="table"}), with 2.9% remaining on a central venous catheter 3 months later in patients aged \< 65 years ([Fig. 4](#f4-kjim-2017-025){ref-type="fig"}). Use of the central venous catheter reduced from a proportional value of 63.1% (percutaneous catheter, 39.0% + tunneled cuffed catheter, 24.1%) to 2.9% in those \< 65 years old, from 60.6% (percutaneous catheter, 37.4% + tunneled cuffed catheter, 23.2%) to 4.5% in those 64 to 74 years old, and from 74.3% (percutaneous catheter, 48.9% + tunneled cuffed catheter, 25.4%) to 11.6% in those ≥ 75 years old. On the other hand, AV access increased among all three groups from a proportional value of 36.9% to 97.1% (\< 65 years), 39.4% to 95.5% (64 to 74 years), and 25.7% to 88.4% (≥ 75 years). It is suggested that much older patients better maintained central venous catheter 3 months after hemodialysis initiation and had a lower conversion rate of AV access.

DISCUSSION
==========

Our results confirm that elderly patients ≥ 75 years are less likely to have AV access, and more likely to receive a central venous catheter. The initial vascular access in elderly patients was mainly via a percutaneous or tunneled cuffed catheter; 48.9% of patients ≥ 75 years initiated dialysis with a percutaneous catheter, 25.4% with a tunneled cuffed catheter, and 25.7% with AV access. Unplanned dialysis initiation was defined as starting dialysis without functional vascular access. More prevalent dialysis initiation with percutaneous catheters suggests that elderly patients are more likely to start dialysis in an unplanned manner, which may be associated with greater mortality rates in incident dialysis patients \[[@b24-kjim-2017-025],[@b25-kjim-2017-025]\]. Results of the present study correspond with the features of unplanned hemodialysis in that patients with percutaneous catheters were more likely to use inotrope and vasopressor agents and have increased inflammatory or infectious markers such as leukocytosis or an elevated level of C-reactive protein.

The present study shows an age-related increase in mortality among all patients who start hemodialysis. We postulate that patients aged ≥ 65 years had a lesser proportion of AV access and more central venous catheter, which linked to unplanned hemodialysis at baseline and the 3-month follow-up assessment. The elderly often have vascular pathologies such as calcification, atherosclerosis, or endothelial dysfunction \[[@b26-kjim-2017-025],[@b27-kjim-2017-025]\]. These vascular changes may have adverse effects on the creation of a fistula and fistula maturation \[[@b28-kjim-2017-025]\], and may be an additional factor in reduced first AV access for elderly patients who start hemodialysis. The present study also showed reduced AV access in patients ≥ 65 years at both baseline and 3 months after hemodialysis initiation.

In this observational study of consecutive incident dialysis patients, we attempted to determine whether initial vascular access type would have an effect on survival comparisons among different age groups. In contrast to previous studies, patients younger than 65 years showed no more risk with a central venous catheter than those receiving AV access. This might be caused by timely conversion to AV access and the exclusion of death, which occurred within 3 months after starting hemodialysis.

We assumed that physicians tend to maintain initial vascular access via percutaneous catheter in patients ≥ 65 years because elderly patients have more comorbidity, which may be caused by an increased risk of complications with procedures or lowered life expectancy. Indeed, the conversion rate showed a difference among groups according to age categories. The rate of conversion decreased with advancing age, and was lowest in patients aged ≥ 75 years. These findings are in agreement with previous studies in which conversion from a catheter to permanent vascular access was associated with an adjusted mortality HR of 0.69 (95% CI, 0.55 to 0.85) \[[@b29-kjim-2017-025]\]. This implies that vascular access for hemodialysis should first consider AV access or conversion to AV access in patients of all ages.

This study has several limitations. First, vascular access associated with mortality in patients with hemodialysis has a higher clinical impact on short-term mortality. However, we excluded patients who died within 3 months of hemodialysis initiation; therefore, the short-term morality could not be further analyzed. Second, there is a possibility of being misunderstood that is no association between vascular access type and long-term mortality in the patients \< 65 years with hemodialysis. Because most of them had switched AV access, its significance might not be apparent. Last, because of the limitation of retrospective study, AV access is not distinguished by fistula and graft. Since grafts are known to have more vascular complications such as an increases of thromboembolic events and infection risk due to endothelial dysfunction, further analysis is needed in the future.

In conclusion, in patients \< 65 years, initial vascular access is not associated with long-term mortality, because most of patients \< 65 years had conversion from a central venous catheter to AV access within 3 months. Thus it is more reasonable to start hemodialysis immediately via an available central venous catheter for an emergent medical condition, rather than delay dialysis owing to vascular access. In patients aged ≥ 65 years, initial vascular access was associated with long-term mortality. "Fistula first" remains a superior strategy for elderly patients and demonstrates it is desirable to change AV access, not maintain the initial central vascular catheter.

KEY MESSAGE
===========

1\. Survival rates for patients who received a central venous catheter aged 65 to 74 years and those ≥ 75 years were reduced, but not for those aged \< 65 years.

2\. As age increased, the conversion rate from central venous catheter to arteriovenous (AV) access decreased.

3\. We suggest that a "fistula first" strategy is superior for elderly patients and demonstrates that it is desirable to change to AV access, and not maintain an initial central vascular catheter.
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###### 

Baseline characteristics and clinical features of patients at the time of hemodialysis initiation by age category and vascular access type

  Characteristic                                                                Entire study population (n = 2,045)   Percutaneous catheter (n = 815)   Tunneled cuffed catheter (n = 491)   Arteriovenous access (n = 739)   *p* value
  ----------------------------------------------------------------------------- ------------------------------------- --------------------------------- ------------------------------------ -------------------------------- -----------
  Age, yr                                                                       58.5 ± 14.5                           59.0 ± 15.6                       58.6 ± 15.3                          59.4 ± 12.5                      0.397
  Male sex                                                                      1,206 (59.0)                          477 (58.5)                        265 (54.0)                           464 (62.9)                       0.008
  Body mass index, kg/m^2^                                                      23.1 ± 6.64                           23.4 ± 8.67                       23.2 ± 4.43                          22.6 ± 5.38                      0.056
  Inotrope and vasopressor use^[a](#tfn1-kjim-2017-025){ref-type="table-fn"}^   803 (39.3)                            395 (49.2)                        219 (27.3)                           189 (23.5)                       \< 0.001
  Hypertension                                                                  1,587 (77.6)                          575(70.6)                         384 (78.2)                           628 (85.0)                       \< 0.001
  Diabetes                                                                      1,034 (50.6)                          393 (48.2)                        249 (50.7)                           392 (53.0)                       0.164
  Heart failure                                                                 61 (3.0)                              31 (3.8)                          13 (2.6)                             17 (2.3)                         0.194
  Hemoglobin, g/dL                                                              9.6 ± 2.35                            9.4 ± 2.73                        8.8 ± 1.95                           10.2 ± 1.92                      \< 0.001
  Albumin, g/dL                                                                 3.3 ± 1.02                            3.1 ± 1.27                        3.2 ± 0.68                           3.5 ± 0.83                       \< 0.001
  White blood cell, 10^3^/mm^3^                                                 9.6 ± 5.88                            11.1 ± 6.81                       8.9 ± 5.39                           8.5 ± 4.61                       \< 0.001
  C-reactive protein, mg/dL                                                     4.8 ± 7.76                            5.9 ± 8.81                        4.1 ± 6.78                           4.0 ± 6.89                       \< 0.001

Values are presented as mean ± SD or number (%).

Use of one of following: dopamine, norepinephrine, epinephrine, dobutamin, vasopressin.

###### 

Baseline characteristics and clinical features of patients according to age category

  Characteristic                                                             \< 65 Years (n = 1,191)   65--74 Years (n = 586)   ≥ 75 Years (n = 268)   *p* value
  -------------------------------------------------------------------------- ------------------------- ------------------------ ---------------------- -----------
  Age, yr                                                                    49.6 ± 11.05              69.3 ± 2.80              79.0 ± 3.53            \< 0.001
  Male sex                                                                   783 (61.3)                336 (56.0)               153 (54.8)             0.031
  Body mass index, kg/m^2^                                                   23.2 ± 7.83               23.0 ± 3.74              22.3 ± 3.79            0.205
  Late referral                                                              603 (47.3)                277 (46.2)               153 (54.8)             0.070
  Past history                                                                                                                                         
   Hypertension                                                              944 (74.0)                503 (83.7)               231 (82.8)             \< 0.001
   Diabetes                                                                  599 (47.0)                375 (62.4)               117 (41.9)             \< 0.001
   Heart failure                                                             31 (2.4)                  18 (3.0)                 14 (5.0)               0.067
  Arteriovenous access type^[a](#tfn2-kjim-2017-025){ref-type="table-fn"}^                                                                             
   Percutaneous catheter                                                     465 (39.0)                219 (37.4)               131 (48.9)             0.001
   Tunneled cuffed catheter                                                  287 (24.1)                136 (23.2)               68 (25.4)              0.001
   Arteriovenous access                                                      439 (36.9)                231 (39.4)               69 (25.7)              0.001
   Conversion rate                                                           94.1                      90.5                     80.3                   \< 0.001
  Chemistry profile                                                                                                                                    
   Hemoglobin, g/dL                                                          9.5 ± 2.51                9.6 ± 2.04               9.4 ± 2.14             0.710
   Albumin, g/dL                                                             3.3 ± 1.19                3.3 ± 0.64               3.2 ± 0.60             0.091
   Serum creatinine, mg/dL                                                   9.0 ± 6.49                7.0 ± 3.49               6.2 ± 3.43             \< 0.001
   eGFR, mL/min/1.73 m^2^                                                    10.7 ± 18.67              11.3 ± 21.36             12.0 ± 14.14           0.519

Values are presented as mean ± SD or number (%).

Arteriovenous fistula or arteriovenous graft.

###### 

Cox proportional analysis for 5-year mortality in all cohort population

  Variable                                                                     HR (95% CI)         *p* value
  ---------------------------------------------------------------------------- ------------------- -----------
  Age, yr                                                                      1.04 (1.03--1.05)   \< 0.001
  Male sex                                                                     1.12 (0.96--1.31)   0.144
  Diabetes                                                                     1.88 (1.59--2.21)   \< 0.001
  Congestive heart failure                                                     1.53 (0.98--2.39)   0.060
  Cardioprotective medication^[a](#tfn3-kjim-2017-025){ref-type="table-fn"}^   1.16 (1.00--1.36)   0.051
  Albumin \< 3.5 g/dL                                                          1.43 (1.22--1.68)   \< 0.001
  Hemoglobin \< 10.0 g/dL                                                      1.17 (1.00--1.37)   0.045
  Percutaneous catheter (ref. AV access)                                       1.78 (1.44--2.21)   \< 0.001
  Tunneled cuffed catheter (ref. AV access)                                    1.64 (1.36--1.98)   \< 0.001

HR, hazard ratio; CI, confidence interval; AV, arteriovenous.

One of following: β-blocker, calcium channel blocker, angiotensin converting enzyme inhibitor, angiotensin receptor antagonist medication.

###### 

Hazard ratios for the mortality in subgroups

  Variable        No. of the deaths/patients (%)   HR (95% CI)      *p* value for interaction                                                       
  --------------- -------------------------------- ---------------- --------------------------- ------------------- ------------------- ----------- ----------
  Age group, yr   319/815 (39.1)                   175/491 (35.6)   140/739 (18.9)              \-                  \-                  \-          \< 0.001
   \< 65          95/465 (20.4)                    60/287 (21.0)    78/439 (17.8)               1.18 (0.89--1.56)   1.28 (0.92--1.78)   Reference   
   65--74         127/219 (58.0)                   69/136 (50.7)    45/231 (19.5)               2.43 (1.82--3.23)   2.27 (1.64--3.13)   Reference   
   ≥ 75           97/131 (74.0)                    46/68 (67.6)     17/69 (24.6)                2.78 (1.92--4.03)   1.92 (1.23--2.98)   Reference   

HR, hazard ratio; CI, confidence interval; AV, arteriovenous.

###### 

Cox proportional analysis for 5-year mortality by initial vascular access for hemodialysis

  Variable                                                                                All cohort          \< 65 Years   65--74 Years        ≥ 75 Years                                                      
  --------------------------------------------------------------------------------------- ------------------- ------------- ------------------- ------------ ------------------- ---------- ------------------- ----------
  Percutaneous catheter                                                                                                                                                                                         
   Unadjusted                                                                             1.70 (1.38--2.09)   \< 0.001      1.18 (0.89--1.56)   0.226        2.43 (1.82--3.23)   \< 0.001   2.78 (1.92--4.03)   \< 0.001
   Adjusted for age                                                                       1.82 (1.47--2.24)   \< 0.001      1.26 (0.95--1.66)   0.096        2.41 (1.81--3.21)   \< 0.001   2.72 (1.88--3.95)   \< 0.001
   Model 1 + sex                                                                          1.85 (1.50--2.29)   \< 0.001      1.27 (0.96--1.68)   0.087        2.43 (1.82--3.23)   \< 0.001   2.74 (1.89--3.97)   \< 0.001
   Model 2 + diabetes, heart failure                                                      1.83 (1.49--2.26)   \< 0.001      1.27 (0.96--1.67)   0.091        2.44 (1.83--3.25)   \< 0.001   2.74 (1.89--3.98)   \< 0.001
   Model 3 + cardioprotective medication^[b](#tfn5-kjim-2017-025){ref-type="table-fn"}^   1.84 (1.51--2.31)   \< 0.001      1.25 (0.94--1.66)   0.111        2.44 (1.83--3.25)   \< 0.001   2.77 (1.90--4.03)   \< 0.001
   Model 4 + albumin \< 3.5 g/dL                                                          1.79 (1.45--2.22)   \< 0.001      1.10 (0.82--1.46)   0.519        2.29 (1.72--3.06)   \< 0.001   2.51 (1.72--3.69)   \< 0.001
   Model 5 + hemoglobin \< 10.0 g/dL                                                      1.78 (1.44--2.21)   \< 0.001      1.10 (0.83--1.47)   0.489        2.33 (1.74--3.12)   \< 0.001   2.49 (1.70--3.66)   \< 0.001
   Model 6 + vascular conversion                                                          1.64 (1.31--2.05)   \< 0.001      1.28 (0.89--1.82)   0.752        1.97 (1.35--2.74)   \< 0.001   1.89 (1.10--3.26)   0.021
  Tunneled cuffed catheter                                                                                                                                                                                      
   Unadjusted                                                                             1.65 (1.38--1.97)   \< 0.001      1.28 (0.92--1.78)   0.134        2.27 (1.64--3.13)   \< 0.001   1.92 (1.23--2.98)   \< 0.001
   Adjusted for age                                                                       1.72 (1.44--2.05)   \< 0.001      0.90 (0.70--1.16)   0.424        2.27 (1.64--3.13)   \< 0.001   1.89 (1.21--2.94)   \< 0.001
   Model 1 + sex                                                                          1.73 (1.45--2.07)   \< 0.001      1.46 (1.05--2.04)   0.024        2.32 (1.68--3.20)   \< 0.001   1.91 (1.22--2.98)   \< 0.001
   Model 2 + diabetes, heart failure                                                      1.77 (1.48--2.11)   \< 0.001      1.48 (1.06--2.07)   0.019        2.30 (1.66--3.17)   \< 0.001   1.91 (1.23--2.98)   \< 0.001
   Model 3 + cardioprotective medication^[b](#tfn5-kjim-2017-025){ref-type="table-fn"}^   1.78 (1.48--2.13)   \< 0.001      1.46 (1.05--2.04)   0.025        2.25 (1.62--3.11)   \< 0.001   1.95 (1.25--3.05)   0.003
   Model 4 + albumin \< 3.5 g/dL                                                          1.64 (1.39--1.97)   \< 0.001      1.10 (0.82--1.46)   0.080        2.25 (1.62--3.11)   \< 0.001   1.89 (1.21--2.96)   0.005
   Model 5 + hemoglobin \< 10.0 g/dL                                                      1.64 (1.36--1.98)   \< 0.001      1.31 (0.93--1.85)   0.115        2.24 (1.61--3.11)   \< 0.001   1.96 (1.25--3.07)   0.003
   Model 6 + vascular conversion                                                          1.41 (1.13--1.75)   0.002         1.04 (0.74--1.45)   0.802        1.93 (1.35--2.74)   \< 0.001   1.34 (1.05--2.26)   0.038

HR, hazard ratio; CI, confidence interval.

*p* value for interaction between vascular access and age group is \< 0.001.

One of following: β-blocker, calcium channel blocker, angiotensin converting enzyme inhibitor, angiotensin receptor antagonist medication.
